Eugenics Is Still a Dangerous Idea
By Dorothy Roberts,
The Inquirer
| 05. 01. 2019
At the turn of the 20th century, U.S. scientists proposed the control of reproduction to advance society based on the idea that genes determine individuals’ socially relevant traits. In 1910, prominent biologist Charles Davenport defined this project, known as eugenics, as “the science of human improvement by better breeding.” The false claim that scientists can isolate, test for, and quantify inherited characteristics that determine success in an unequal society was essential to eugenicists’ theory that social inequality comes from biology.
Eugenicists’ ideas found fertile ground in America, where they provided a scientific framework to justify the efforts of U.S. elites to preserve the unjust social order they had violently erected in prior centuries. That legacy has spanned decades into the present day.
One of the most widespread and devastating eugenicist weapons has been state-imposed sterilization to rid society of “socially inadequate” members. In March 1924, Virginia lawmakers passed a law that authorized the forced sterilization of people confined to government asylums because they were deemed “feebleminded.” In the 1927 case Buck v. Bell, Justice Oliver Wendell Holmes upheld...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...